Central Glucagon-Like Peptide-1 Agonism Ameliorates Colonic Inflammation in a Murine Model of Inflammatory Bowel Disease

Desai B, Francis KL, Bryan CL, Connolly J et al. · preprint server · Oct 24, 2026
DOI 10.64898/2026.10.22.761061 · PubMed 42996002

Design

Animal study · Intermediate outcome

Match to healthy normal-weight adults aged 55–75

Not human evidenceVERY_INDIRECT: the study was done in diet-induced obese mice with dextran sodium sulfate-induced colitis, which is non-human evidence.

Could weight loss explain it?

PossiblyNo body weight, food intake or glycaemic data are reported, so under the presumption that GLP-1 effects are confounded with weight and metabolic change, mediation stays possible. The authors give the central dose as one that, peripherally, falls below the threshold needed to affect food intake and body weight, which argues for a weight-independent central mechanism but is a dose argument rather than a mediation analysis, a weight-matched comparison or a measurement taken before weight loss.

Study tier

PreliminaryPRELIMINARY because the record is a preprint and has not been peer reviewed, which is the level the model gives anything not peer reviewed; the exception that leaves a preprint unrated applies only to a preprint holding no outcome data, and this one reports outcomes. The underlying design, an animal study in a chemically induced colitis model with no group sizes, effect sizes or statistics in the abstract, would itself sit at VERY_LOW, so the rating credits it with no more than preclinical weight.

Assessment

Version 2 · Two independent AI reviews agreed · Nov 6, 2026

Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75. This item has not been peer reviewed.

In diet-induced obese mice given dextran sodium sulfate to induce colitis, researchers compared semaglutide injected into the body with semaglutide delivered directly into the brain. Both colitis severity and tissue injury were reduced by semaglutide given peripherally compared with vehicle, and the benefit was largely reproduced by a low dose given into the brain, below the amount that affects food intake and body weight when given peripherally. The authors conclude that activating GLP-1 receptors in the brain is enough to explain the anti-inflammatory effect in the gut. This is an animal study, released as a preprint without peer review, and the abstract reports no numbers of animals, effect sizes or statistics.